Previous 10 | Next 10 |
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Amylyx To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - April 7, 2024) - Faruqi & Faruqi, LLP, a leading national se...
2024-04-07 04:59:02 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Spotify . Read the full article on Seeking Alpha For further details see: Wall Street Breakfast: The Week Ahead
2024-04-05 15:00:12 ET More on the markets SPY: The Correction May Be Massive S&P 500: International Risk Assessment My Current View Of The Market: April 2024 Edition (Technical Analysis) S&P 500 holds its bullish trend as it defends the 20-day MA yet...
2024-04-04 07:32:38 ET More on Amylyx Pharmaceuticals An ALS Drug Fails Again Amylyx Pharmaceuticals: Q4 Earnings Insight And PHOENIX Trial Implications Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2023 Earnings Call Transcript Mizuho downgrades Amylyx to Neutral a...
- Based on topline results from the Phase 3 PHOENIX trial of AMX0035 in ALS, Amylyx has started a process with the FDA and Health Canada of voluntarily discontinuing the marketing authorizations for RELYVRIO/ALBRIOZA - RELYVRIO/ALBRIOZA will no longer be available for new patients a...
Do you, or did you, own securities of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)? Did you purchase your securities between November 11, 2022 and November 8, 2023, inclusive? Did you lose money in your investment in Amylyx Pharmaceuticals, Inc.? Do you want to discuss your rights? NEW...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Amylyx To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - April 1, 2024) - Faruqi & Faruqi, LLP, a leading national se...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Amylyx To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - March 20, 2024) - Faruqi & Faruqi, LLP, a leading national s...
2024-03-19 09:09:46 ET More on Seelos Therapeutics Seelos Therapeutics files for 3.4M shares secondary offering Mind Medicine sends psychedelic stocks higher after FDA status for LSD formulation Seeking Alpha’s Quant Rating on Seelos Therapeutics Histo...
2024-03-18 10:00:18 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Johnson & Johnson, Boston...
News, Short Squeeze, Breakout and More Instantly...
Amylyx Pharmaceuticals Inc. Company Name:
AMLX Stock Symbol:
NASDAQ Market:
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in a fireside chat presentation at the Goldman Sachs 45th Annual Global Healthcare Conference. The conference is being conducted in-person in Miam...
2024-05-10 16:30:03 ET H.C. Wainwright analyst issues BUY recommendation for AMLX on May 10, 2024 02:01PM ET. The previous analyst recommendation was Buy. AMLX was trading at $1.775 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...